高级检索
当前位置: 首页 > 详情页

The polymorphism rs4705342 in the promoter of miR-143/145 is related to the risk of epithelial ovarian cancer and patient prognosis

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Department of Gynecology, The People’s Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China [2]Department of Gynecology, The People’s Hospital of Tangshan, Tangshan, Hebei, China [3]Department of Gynecology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
出处:
ISSN:

关键词: ovarian cancer rs4705342 rs353292 risk prognosis

摘要:
ObjectiveTo evaluate the effects of two genetic variants in the promoter of the miR-143/145 cluster on the risk of epithelial ovarian cancer (EOC) and the prognosis of EOC patients. Study designGenotypes were determined by the polymerase chain reaction and ligase detection reaction method in 563 EOC patients and 576 healthy women. The expression of miR-143 and miR-145 were detected by quantitative real-time polymerase chain reaction (qRT-PCR) in fifty-two EOC tissues. ResultsThe rs4705342 CC genotype frequencies in EOC patients were higher than those in the controls (P = 0.014). Furthermore, the CC genotype of rs4705342 was associated with an advanced FIGO stage of EOC patients (P = 0.046). Patients with the rs4705342 CC genotype had shorter progression-free survival (PFS) and overall survival (OS) times than those carrying the TT genotype in multivariable analysis adjusting for clinical variables (HR = 1.30, 95% CI = 1.04-1.62, P = 0.020; HR = 1.33, 95% CI = 1.05-1.70, P = 0.020). In addition, the miR-145 levels were lower in EOC tissues with the rs4705342 CC genotype than in those with the TT genotype (P = 0.005). ConclusionThe CC genotype of rs4705342 was related to an increased risk of EOC and poor prognosis of EOC patients, and rs4705342 may serve as a molecular marker for predicting the development of EOC and the clinical outcome of EOC patients.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院分区:
出版当年[2023]版:
大类 | 3 区 医学
小类 | 3 区 肿瘤学
最新[2025]版:
大类 | 3 区 医学
小类 | 4 区 肿瘤学
JCR分区:
出版当年[2023]版:
Q2 ONCOLOGY
最新[2024]版:
Q2 ONCOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版] 出版后一年[2024版]

第一作者:
第一作者机构: [1]Department of Gynecology, The People’s Hospital of Shijiazhuang, Hebei Medical University, Shijiazhuang, Hebei, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:42329 今日访问量:0 总访问量:1365 更新日期:2025-08-01 建议使用谷歌、火狐浏览器 常见问题

技术支持:重庆聚合科技有限公司 地址:河北省石家庄市健康路12号